Heart Failure Clinical Trial
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in participants with type 2 diabetes, cardiovascular risk factors, and moderate to severely impaired renal function.
Inclusion criteria :
Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) â‰¥7%.
Estimated glomerular filtration rate (eGFR) â‰¥25 and â‰¤60 milliliter/minute (mL/min)/1.73 square meter (m^2).
Age 18 years or older with at least one major cardiovascular risk factor or age 55 years or older with at least two minor cardiovascular risk factors.
Signed written informed consent.
Antihyperglycemic treatment has not been stable within 12 weeks prior to screening.
Planned coronary procedure or surgery after randomization.
Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization.
Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the study.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 648 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.